Day: June 18, 2020

WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference being held virtually on June 23, 2020.Details of the fireside chat are below:Event:  BMO 2020 Prescriptions for Success Healthcare ConferenceDate:  Tuesday, June 23, 2020Location:  https://bmo.qumucloud.com/view/2020-healthcare-entasis-therapeuticsTime:  3:30 PM ETAdditionally, Dr. Perros will hold 1-on-1 virtual investor meetings at the conference. Investors attending the conference virtually who are interested in meeting with...

WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) — Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, and Marc Schegerin, M.D., chief financial officer and chief operating officer, are scheduled to make a presentation at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference at 11:00 a.m. ET on Tuesday, June 23, 2020. Morphic will give an update on the company’s progress across its portfolio of oral small molecule integrin inhibitors.A live webcast of the presentation will be available on the Investors section of Morphic’s website at https://www.morphictx.com. An archived replay will be available on the company’s...

The Gamma Knife Center S.A. Operates the Only Gamma Knife Facility in EcuadorSan Francisco, CA, June 18, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — American Shared Hospital Services (NYSE American: AMS) (“AMS”), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced that its 81% owned subsidiary, GK Financing, LLC (“GKF”), has completed the acquisition of approximately 98% of the total outstanding shares of Gamma Knife Center Ecuador S.A. (“GKC Ecuador”) purchased from GKC Ecuador’s majority shareholders Global Medical Investments GMI AB, Scandinavian Care Investments AB, and Brock Investment Limited (the “Acquisition”). At a later date, AMS plans to acquire the remaining outstanding shares of GKC Ecuador by entering into a separate...

TEMPE, Ariz. and HOUSTON, June 18, 2020 (GLOBE NEWSWIRE) — First Solar, Inc. (Nasdaq: FSLR) today announced that it had signed a 15-year power purchase agreement (PPA) with Dow, Inc. (NYSE: DOW) for its Gulf Coast operations. Dow’s Texas Operations is the largest petrochemical site in the western hemisphere. First Solar had previously disclosed the execution of the PPA without identifying the offtaker.Under the agreement, First Solar will supply Dow with renewable energy from 75 percent of its 200-megawatt (MW)AC Horizon Solar project in Frio County, Texas. The project will utilize First Solar’s high-performance, eco-efficient Series 6 photovoltaic (PV) modules, designed and developed at the Company’s research and development (R&D) centers in California and Ohio. The Series 6 modules that will power the project utilize a range...

RALEIGH, N.C., June 18, 2020 (GLOBE NEWSWIRE) — Between 2007-2017, 78 novel adult cancer agents were approved by the U.S. Food and Drug Administration,1 but none of those drugs were researched to determine effectiveness for pediatric cancers.That is about to change on August 18 when the RACE Act – The Research to Accelerate Cures and Equity for Children Act – goes into effect. Passed in 2017, the RACE Act amends the existing PREA – Pediatric Research Equity Act – and eliminates the exemption from PREA requirements for cancer drugs that have orphan status. The new law requires pediatric evaluation of new drugs and biologics intended for the treatment of adult cancers and directed at a molecular target substantially relevant to the growth or progression of pediatric cancer.Clinical research companies and their pediatric research specialists,...

MELBOURNE, Australia, June 18, 2020 (GLOBE NEWSWIRE) — Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to report important progress towards the commencement of recruitment in the Phase 3 clinical trial of CYP-004, its Cymerus™ mesenchymal stem cell (MSC) product for osteoarthritis. This trial is sponsored by the University of Sydney, and funded by an Australian Government National Health and Medical Research Council (NHMRC) competitive Project Grant.Key Highlights:Phase 3 clinical trial of CYP-004 approved by the University of Sydney HREC, a key milestone to trial commencementTGA confirms that the trial can be conducted under notification-only CTN schemeLed by the University of Sydney and funded by NHMRC, the 440-patient trial...

CHICAGO, June 18, 2020 (GLOBE NEWSWIRE) — Century Aluminum Company (NASDAQ: CENX) (“Century”) announced today a proposed offering of $250 million aggregate principal amount of senior secured notes due 2025 (the “New Notes”). Century also announced today that it has commenced a cash tender offer (the “Tender Offer”) for any and all of its $250,000,000 outstanding principal amount of 7.500% Senior Secured Notes due 2021 (the “Existing Notes”). Net proceeds from the sale of the New Notes, together with available cash on hand, will be used to finance the purchase of the Existing Notes in the Tender Offer and the redemption of any Existing Notes not acquired in the Tender Offer, as well as to pay fees and expenses related to the offering of the New Notes.The New Notes will be offered and sold to qualified institutional buyers in reliance...

PALO ALTO, Calif., June 18, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, has entered into a strategic collaboration with the University of Florida to translate research in genetically driven disease towards clinical development and potential commercialization. The partnership combines University of Florida’s prowess in studying genetically driven disease, including its capabilities in gene therapy, with BridgeBio’s expertise in efficiently advancing therapeutics from the academic laboratory through preclinical studies and into human testing.BridgeBio believes that, too often, promising research in academia sits on the shelf without partners to move it forward. The company’s mission is to bring as much of that research forward as possible, by...

WINNIPEG, Manitoba, 18 juin 2020 (GLOBE NEWSWIRE) — The North West Company Inc. (la « Société » ou « North West ») a annoncé aujourd’hui avoir émis 70 millions USD en billets de premier rang, dont le produit sera utilisé pour réduire les montants prélevés des facilités de crédits dans les Activités canadiennes ainsi qu’à d’autres fins générales de l’entreprise. La capacité supplémentaire des facilités de crédit dans les Activités canadiennes provenant de ce nouveau financement devrait être utilisée pour rembourser les billets de premier rang de 70 millions USD lorsqu’ils arriveront à échéance le 16 juin 2021.Les nouveaux billets de premier rang ont été émis dans le cadre d’un placement privé en deux tranches ; 35 millions USD de titres de premier rang à un taux de 2,88 % qui arriveront à échéance...